This website is designed to provide information about the Add-Aspirin Trial, both for people taking part in the trial (participants) and collaborators. Please use the menus at the top of the screen to find out more about the trial.
Add-Aspirin is a large randomised clinical trial, which is taking place in the UK and India. It will recruit 11,000 participants to help find out whether regular aspirin use after treatment for an early stage cancer can prevent the cancer from coming back and preventing deaths.
Congratulations to our top 5 recruiting centres:
*FOR GENERAL AND CLINICAL QUERIES, PLEASE CHECK OUR FAQs*
Please note the Randomisation phone line will be closed from 5pm on Friday 22nd December and will reopen at 9am on 2nd January 2018.
The last date for sending translational samples to biobanks will be 30th December 2017.
Wales Cancer Bank will re-open on Tuesday 2nd Jan 2018 and Tayside Tissue Bank will reopen on Wednesday 3rd Jan 2018.
We aim to recruit 3100 individuals who have had surgery to remove an early stage breast cancer.
Top recruiters: Worcestershire Royal Hospital, Royal Marsden Hospitals, Churchill Hospital Oxford
PARTICIPANTS REGISTERED: 1738
PARTICIPANTS RANDOMISED: 1376
We aim to to recruit 2600 individuals who have had surgery to remove an early stage bowel cancer.
Top recruiters: Bristol Haematology & Oncology Centre, St James 's University Hospital, Darlington Memorial Hospital
PARTICIPANTS REGISTERED: 996
PARTICIPANTS RANDOMISED: 759
We aim to recruit 2100 individuals who have had surgery or a combination of chemotherapy and radiotherapy to treat a cancer of the stomach or oesophagus (food pipe).
The Christie, St James's University Hospital, Manor Hospital, Leicester Royal Infirmary
PARTICIPANTS REGISTERED: 128
PARTICIPANTS RANDOMISED: 93
We aim to recruit 2120 individuals who have had surgery or radiotherapy to treat an early stage prostate cancer.
Top recruiters: UCHW, University Hospital of Wales, Bristol Haematology & Oncology Centre
PARTICIPANTS REGISTERED: 790
PARTICIPANTS RANDOMISED: 632